FDA Approves AstraZeneca's Truqap as First Targeted Treatment for PTEN-Deficient Prostate Cancer

summarizeSummary

AstraZeneca's Truqap has received US FDA approval for PTEN-deficient metastatic prostate cancer, becoming the first targeted treatment for this aggressive disease. This approval is based on positive Phase III trial results demonstrating significant clinical benefit.

check_boxKey Events

• US FDA Approval for Truqap

  AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone received US FDA approval for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.

• First-in-Class Targeted Treatment

  Truqap is approved as the first and only targeted treatment for this specific, aggressive form of prostate cancer, which affects approximately one in four patients with mAPMN/S prostate cancer.

• Significant Clinical Benefit

  The approval is based on the CAPItello-281 Phase III trial, which showed a statistically significant 19% reduction in the risk of radiographic disease progression or death, with a 7.5-month improvement in median radiographic progression-free survival.

• Companion Diagnostic Approved

  Concurrently, the FDA also approved a companion diagnostic test to detect PTEN deficiency in prostate adenocarcinoma tumors, enabling targeted patient selection.

auto_awesomeAnalysis

The US FDA approval of Truqap for PTEN-deficient metastatic prostate cancer is a significant milestone. This marks the first and only targeted treatment for an aggressive form of prostate cancer, addressing a critical unmet need for approximately 35,000 US patients annually. The approval, based on strong Phase III data showing a 19% reduction in disease progression or death, reinforces AstraZeneca's leadership in oncology and expands its market presence in a major cancer indication.